TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00813553

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: daily
Study: NCT04644419

Intervention type: OTHER
Intervention: none (observational study)
Description: This is an observational study and does not include intervention delivery.
Study: NCT02657252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Sclerotherapy of telangiectasis in one lower limb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol with Glucose
Description: Sclerotherapy of telangiectasis in one lower limb.
Study: NCT00849693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
Study: NCT00002735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: Cisplatin and 5-Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
Study: NCT02697955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: 50 mg bupivacaine and 50 μg adrenalin
Study: NCT00002735

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Description: 180 cGy per day, Days 1-5, every week for eight weeks
Study: NCT02697955

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 mg sodium chloride pr. ml (0,9 %)
Study: NCT03721081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%/Epi 1:200000
Description: Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Na Cl 0.9%/Epi 1:200000
Description: Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
Study: NCT00459407

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo biopsy
Study: NCT03378934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.
Study: NCT02448173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OncoVAX and Surgery
Description: OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection of Stage II colon cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of Stage II colon cancer
Study: NCT03855839

Intervention type: DEVICE
Intervention: Posture shirt
Description: Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.

Intervention type: DEVICE
Intervention: Compression shirt
Description: Compression shirts are designed for recreational sport activities and can be bought in any local sports store
Study: NCT04269512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymph node dissection
Description: At least 10 lymph nodes must be removed.
Study: NCT04655677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20-directed CAR-T cells
Description: Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Study: NCT01816646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
Study: NCT00973830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Guide and Brief Counseling
Description: If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Guide and Brief Counseling
Description: If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
Study: NCT01907529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel, epirubicin and cyclophosphamide
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, epirubicin and cyclophosphamide plus endostar
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
Study: NCT04076124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS-DLPFC
Description: Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS-DLPFC
Description: Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC or Sham rTMS-DLPFC
Description: Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
Study: NCT04137172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic (IPOM) hernioplasty without repair
Description: Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap .
Study: NCT03852615

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pre operation Blood sample for AMH
Description: Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
Study: NCT01668927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor
Study: NCT04137172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
Description: Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
Description: The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
Study: NCT01668927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton Pump Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor
Study: NCT01240993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Toddlers Program
Description: This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
Study: NCT00300872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
Study: NCT03852615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre operation Blood sample for AMH
Description: Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
Study: NCT00300872

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous positive airway pressure (CPAP)
Description: Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
Study: NCT03832868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit timing of receipt of the ICDs implantation decision aid
Description: The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-visit timing of receipt of the ICDs implantation decision aid
Description: The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
Study: NCT00416767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT02412644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apremilast
Study: NCT01310595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual mobilization on cervical spine
Description: Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra-red therapy with self exercise pamphlet
Description: Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
Study: NCT01759784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraventricular injection
Description: intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
Study: NCT03465735

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Vascular Boot
Description: The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Anticoagulant therapy will be decided by physician and patient.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Anticoagulant therapy will be decided by physician and patient.
Study: NCT03114241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
Study: NCT04196036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day of vitrification
Description: Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day of vitrification
Description: Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
Study: NCT00459407

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Undergo biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study: NCT02077049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serious games
Description: Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional self-training
Description: Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
Study: NCT00780000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvespimycin
Description: Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
Study: NCT02734992

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT+ MTAU
Description: Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control +MTAU
Description: Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
Study: NCT01369693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal administration of nicotine
Description: Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal administration of nicotine
Description: Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal administration of nicotine
Description: Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal administration of nicotine
Description: Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
Study: NCT01527604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avenanthramide-enriched oats
Description: avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined flour absent avenanthramides
Description: refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
Study: NCT03020524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD4 T-Cells
Description: all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous CD4 T-Cells
Description: all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous CD4 T-Cells
Description: all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
Study: NCT04051567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: In LDA group, patients were asked for taking 100mg aspirin per night;